Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Small Cell Lung Carcinoma 16Breast Neoplasms 13Sarcoma 10Carcinoma, Hepatocellular 8Esophageal Squamous Cell Carcinoma 7Lung Neoplasms 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Carcinoma 5Stomach Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Thyroid Neoplasms 3Recurrence 3Paraganglioma 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × anlotinib × Clear all
NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
33 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07562581 2026-05-01

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2 Not yet recruiting
48 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Peking Union Medical College Hospital

Phase 2 Completed
27 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Henan Cancer Hospital

Phase 2 Completed
42 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡